Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU.
Mov Disord. 2019 Aug;34(8):1203-1209. doi: 10.1002/mds.27769. Epub 2019 Jun 24.
Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative.
Chakrabarty AC, Bennett JI, Baloch TJ, Shah RP, Hawk C, Natof T.
Cureus. 2023 May 25;15(5):e39486. doi: 10.7759/cureus.39486. eCollection 2023 May.
Abnormal Involuntary Movement Scale (AIMS).
[No authors listed]
Psychopharmacol Bull. 1988;24(4):781-3.
Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
Caroff SN, Leong SH, Roberts CB, Berkowitz RM, Campbell EC.
J Clin Psychopharmacol. 2020 Jul/Aug;40(4):373-380. doi: 10.1097/JCP.0000000000001229.
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop.
Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M; Tardive Dyskinesia Assessment Working Group.
J Clin Psychiatry. 2018 May/Jun;79(3):17cs11959. doi: 10.4088/JCP.17cs11959.
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
Hauser RA, Barkay H, Wilhelm A, Wieman M, Savola JM, Gordon MF.
Parkinsonism Relat Disord. 2022 Apr;97:47-51. doi: 10.1016/j.parkreldis.2022.02.017. Epub 2022 Mar 2.
Tardive dyskinesia: Out of the shadows.
Hauser RA, Truong D.
J Neurol Sci. 2018 Jun 15;389:1-3. doi: 10.1016/j.jns.2018.02.009. Epub 2018 Feb 5.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.
Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.
Assessment and Treatment of Abnormal Involuntary Movements: A Clinically Focused Narrative Review.
Petriceks A, Vyas CM, Paudel S, Donovan AL, Van Alphen MU, Stern TA.
Harv Rev Psychiatry. 2024 Mar-Apr 01;32(2):47-57. doi: 10.1097/HRP.0000000000000390.
